Karyopharm Therapeutics Statistics
Karyopharm Therapeutics (25K0) Stock Statistics & Valuation Metrics
Total Valuation
Karyopharm Therapeutics has a market cap or net worth of EUR 353.36K. The enterprise value is EUR 473.81M.
- Market Cap
- EUR 353.36K
- Enterprise Value
- EUR 473.81M
Share Statistics
Karyopharm Therapeutics has 22,681,460 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 22,681,460
- Owned by Insiders
- 3.63%
- Owned by Institutions
- 26.56%
Financial Efficiency
Karyopharm Therapeutics’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -236.62%.
- Return on Equity (ROE)
- 0.67
- Return on Assets (ROA)
- -1.81
- Return on Invested Capital (ROIC)
- -236.62%
- Return on Capital Employed (ROCE)
- -5.55
- Revenue Per Employee
- 640.64K
- Profits Per Employee
- -859.82K
- Employee Count
- 228
- Asset Turnover
- 1.35
- Inventory Turnover
- 1.47
Valuation Ratios
The current PE Ratio of Karyopharm Therapeutics is -0.00. Karyopharm Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- -0.00
- Price to FCF
- -0.01
- Price to Operating Cash Flow
- -0.01
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Karyopharm Therapeutics had revenue of 146.07M and earned -196.04M in profits. Earnings per share was -17.93.
- Revenue
- 146.07M
- Gross Profit
- 140.12M
- Operating Income
- -90.71M
- Pretax Income
- -196.00M
- Net Income
- -196.04M
- EBITDA
- -149.85M
- Earnings Per Share (EPS)
- -17.93
Cash Flow
In the last 12 months, operating cash flow was -65.35M and capital expenditures 0, giving a free cash flow of -65.35M billion.
- Operating Cash Flow
- -65.35M
- Free Cash Flow
- -65.35M
- Free Cash Flow per Share
- -2.26
Dividends & Yields
Karyopharm Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -12977.83%
- Earnings Yield
- -34983.15%
Stock Price Statistics
- Beta
- 1.13
- 52-Week Price Change
- -99.54%
- 50-Day Moving Average
- 0.89
- 200-Day Moving Average
- 4.87
- Relative Strength Index (RSI)
- 27.78
- Average Volume (3m)
- 3,387
Important Dates
Karyopharm Therapeutics upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Karyopharm Therapeutics as a current ratio of 1.12, with Debt / Equity ratio of -79.75%
- Current Ratio
- 1.12
- Quick Ratio
- 1.08
- Debt to Market Cap
- 2.82
- Net Debt to EBITDA
- -1.15
- Interest Coverage Ratio
- -1.98
Taxes
In the past 12 months, Karyopharm Therapeutics has paid 43.00K in taxes.
- Income Tax
- 43.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Karyopharm Therapeutics EV to EBITDA ratio is -0.92, with an EV/FCF ratio of -2.47.
- EV to Sales
- 1.10
- EV to EBITDA
- -0.92
- EV to Free Cash Flow
- -2.47
- EV to Operating Cash Flow
- -2.47
Balance Sheet
Karyopharm Therapeutics has EUR 65.11M in cash and marketable securities with EUR 215.88M in debt, giving a net cash position of -EUR 150.78M billion.
- Cash & Marketable Securities
- EUR 65.11M
- Total Debt
- EUR 215.88M
- Net Cash
- -EUR 150.78M
- Net Cash Per Share
- -EUR 6.65
- Tangible Book Value Per Share
- -EUR 11.41
Margins
Gross margin is 95.88%, with operating margin of -56.17%, and net profit margin of -153.28%.
- Gross Margin
- 95.88%
- Operating Margin
- -56.17%
- Pretax Margin
- -153.30%
- Net Profit Margin
- -153.28%
- EBITDA Margin
- -119.94%
- EBIT Margin
- -120.04%
Analyst Forecast
The average price target for Karyopharm Therapeutics is EUR 5.23, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 5.23
- Price Target Upside
- 26044.21% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -0.18%
- EPS Growth Forecast
- 17.56%
